[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,081,284
  • Shares Outstanding, K 82,258
  • Annual Sales, $ 39,210 K
  • Annual Income, $ -311,350 K
  • EBIT $ -359 M
  • EBITDA $ -360 M
  • 60-Month Beta 1.95
  • Price/Sales 250.38
  • Price/Cash Flow N/A
  • Price/Book 6.36

Options Overview Details

View History
  • Implied Volatility 62.16% (+3.86%)
  • Historical Volatility 76.02%
  • IV Percentile 41%
  • IV Rank 14.40%
  • IV High 153.30% on 12/05/25
  • IV Low 46.82% on 08/18/25
  • Expected Move (DTE 3) 2.34 (2.12%)
  • Put/Call Vol Ratio 1.06
  • Today's Volume 128
  • Volume Avg (30-Day) 524
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 10,143
  • Open Int (30-Day) 6,354
  • Expected Range 108.06 to 112.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.64
  • Number of Estimates 9
  • High Estimate $-0.38
  • Low Estimate $-1.04
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +32.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.52 +30.62%
on 06/16/26
130.05 -15.11%
on 06/25/26
+24.19 (+28.07%)
since 06/12/26
3-Month
69.48 +58.89%
on 06/03/26
130.05 -15.11%
on 06/25/26
+21.87 (+24.70%)
since 04/13/26
52-Week
36.65 +201.23%
on 08/11/25
130.05 -15.11%
on 06/25/26
+65.92 (+148.20%)
since 07/11/25

Most Recent Stories

More News
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies  KT-621...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations

Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass.,...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models  KT-579 Phase 1 healthy volunteer...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data

Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing...

KYMR : 110.40 (-7.50%)
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ...

KYMR : 110.40 (-7.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 123.90
2nd Resistance Point 120.59
1st Resistance Point 115.49
Last Price 110.40
1st Support Level 107.09
2nd Support Level 103.78
3rd Support Level 98.68

See More

52-Week High 130.05
Last Price 110.40
Fibonacci 61.8% 94.37
Fibonacci 50% 83.35
Fibonacci 38.2% 72.33
52-Week Low 36.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.